[go: up one dir, main page]

AU2002231223A1 - Compositions and methods for treating hematologic malignancies and multiple drug resistance - Google Patents

Compositions and methods for treating hematologic malignancies and multiple drug resistance

Info

Publication number
AU2002231223A1
AU2002231223A1 AU2002231223A AU3122302A AU2002231223A1 AU 2002231223 A1 AU2002231223 A1 AU 2002231223A1 AU 2002231223 A AU2002231223 A AU 2002231223A AU 3122302 A AU3122302 A AU 3122302A AU 2002231223 A1 AU2002231223 A1 AU 2002231223A1
Authority
AU
Australia
Prior art keywords
compositions
methods
drug resistance
multiple drug
hematologic malignancies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002231223A
Other languages
English (en)
Inventor
Sean P Colgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2002231223A1 publication Critical patent/AU2002231223A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002231223A 2000-10-26 2001-10-25 Compositions and methods for treating hematologic malignancies and multiple drug resistance Abandoned AU2002231223A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24354200P 2000-10-26 2000-10-26
US60/243,542 2000-10-26
PCT/US2001/049856 WO2002034291A2 (fr) 2000-10-26 2001-10-25 Compositions et procedes servant a traiter des malignites hematologiques et la resistance a des medicaments multiples

Publications (1)

Publication Number Publication Date
AU2002231223A1 true AU2002231223A1 (en) 2002-05-06

Family

ID=22919154

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002231223A Abandoned AU2002231223A1 (en) 2000-10-26 2001-10-25 Compositions and methods for treating hematologic malignancies and multiple drug resistance

Country Status (3)

Country Link
US (1) US7105656B2 (fr)
AU (1) AU2002231223A1 (fr)
WO (1) WO2002034291A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546143B2 (en) * 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
ES2649817T3 (es) 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
WO2004066949A2 (fr) * 2003-01-28 2004-08-12 Rexahn Corporation Oligonucleotides anti-sens inhibant l'expression du hif-1
ES2333794T3 (es) * 2003-01-31 2010-03-01 Rexahn Pharmaceuticals, Inc. Oligonucleotidos que inhiben la expresion de hif-1.
FR2860237B1 (fr) 2003-09-30 2006-03-10 Centre Nat Rech Scient Polypeptide d'interaction comprenant un motif heptapeptidique et un domaine de penetration cellulaire
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
NZ555644A (en) 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
SMT202100234T1 (it) * 2009-12-04 2021-05-07 Oncoc4 Lnc Usi di inibitori di fattori inducibili da ipossia
WO2018085208A1 (fr) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Procédés d'inhibition de virus à l'aide de compositions ciblant l'interaction tsg101-ubiquitine
US20230212296A1 (en) * 2020-06-02 2023-07-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968735A (en) * 1992-11-12 1999-10-19 Max Delbruck-Centrum Fur Molekular Medizin Berlin Vector for the expression of therapy-relevant genes
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
WO1998020038A1 (fr) * 1996-11-05 1998-05-14 Board Of Regents, The University Of Texas System Compositions et utilisations relatives a la sentrine, une proteine de protection contre la mort cellulaire
WO1999009046A1 (fr) 1997-08-21 1999-02-25 Quark Biotech, Inc. Genes regules au niveau de l'hypoxemie
US5985664A (en) * 1998-12-17 1999-11-16 Isis Pharmaceuticals, Inc. Antisense modulation of Sentrin expression
GB9911047D0 (en) * 1999-05-12 1999-07-14 Isis Innovation Assay method and means
SE0002551D0 (sv) * 2000-07-06 2000-07-06 Pharmacia & Upjohn Ab Screening methods

Also Published As

Publication number Publication date
US20050203036A1 (en) 2005-09-15
WO2002034291A2 (fr) 2002-05-02
US7105656B2 (en) 2006-09-12
WO2002034291A3 (fr) 2003-05-30

Similar Documents

Publication Publication Date Title
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2001294808A1 (en) Catecholamine pharmaceutical compositions and methods
AU2002335647A1 (en) Methods and devices for electrosurgery
AU8547001A (en) Composition and method for inhibiting platelet aggregation
AU2001245437A1 (en) Lightweight methods and compositions for well treating
HU0103078D0 (en) Pharmaceutical compositions and methods for treating cataracts
AU2002230407A1 (en) Compounds and methods for treating multidrug resistance
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU5326100A (en) Pharmaceutical compositions and methods for use
AU5565099A (en) Pharmaceutical compositions and methods for use
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002236626A1 (en) Compositions and methods for treating hyperpigmentation
AU2002231223A1 (en) Compositions and methods for treating hematologic malignancies and multiple drug resistance
AU2001243394A1 (en) Compounds and methods
AU2002249888A1 (en) Microbial blend compositions and methods for their use
AUPQ872300A0 (en) Compounds and methods
IL153487A0 (en) Pharmaceutical compositions and methods for use
AU2001233932A1 (en) Method and composition
AU2001249409A1 (en) Ricin inhibitors and methods for use thereof
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
IL153897A0 (en) Pharmaceutical compositions and methods for use
AU2001278951A1 (en) Compounds and methods
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU4328700A (en) Pseudomycin antifungal compositions and methods for their use